Literature DB >> 9890685

Renal diseases in ankylosing spondylitis: review of the literature illustrated by case reports.

E S Strobel1, E Fritschka.   

Abstract

Ankylosing spondylitis (AS) can be accompanied by extraarticular manifestations in the cardiovascular, pulmonary, neurologic and renal organs. Secondary renal amyloidosis is the most common cause of renal involvement in AS (62%) followed by IgA nephropathy (30%), mesangioproliferative glomerulonephritis (5%) as well as rarely membranous nephropathy (1%), focal segmental glomerulosclerosis (1%) and focal proliferative glomeruleonephritis (1%). Treatment associated nephrotoxicity may result from non-steroidal anti-inflammatory drugs or disease modifying agents. The purpose of this paper was to alert for the possibility of renal damage in AS and to analyse the frequencies of different etiologies of renal involvement. Two typical case reports of renal involvement in AS are presented to illustrate the clinical course of such patients. Renal side effects and possible pre-existing renal diseases should be taken into account while choosing the appropriate medication for patients with AS.

Entities:  

Mesh:

Year:  1998        PMID: 9890685     DOI: 10.1007/bf01451293

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  37 in total

1.  Isolated glomerulonephritis with mesangial IgA deposits.

Authors:  J G Sissons; D F Woodrow; J R Curtis; D J Evans; P E Gower; J C Sloper; D K Peters
Journal:  Br Med J       Date:  1975-09-13

Review 2.  [AA-amyloidosis in inflammatory rheumatic diseases. A report of clinical experiences].

Authors:  F Schneider
Journal:  Z Rheumatol       Date:  1992 Jul-Aug       Impact factor: 1.372

3.  Regression of reactive systemic amyloidosis due to ankylosing spondylitis following the administration of colchicine.

Authors:  A Escalante; G R Ehresmann; F P Quismorio
Journal:  Arthritis Rheum       Date:  1991-07

4.  Endstage renal disease in a case of AS and amyloidosis.

Authors:  J Pascual; J L Teruel; J Ortuño
Journal:  J Rheumatol       Date:  1992-01       Impact factor: 4.666

5.  IgA-nephropathia in a patient with ankylosing spondylitis.

Authors:  G N Andersen
Journal:  Scand J Rheumatol       Date:  1992       Impact factor: 3.641

6.  Amyloidosis and ankylosing spondylitis.

Authors:  P Gallar; A Oliet; E Hernandez; A Vigil; M Crespo
Journal:  Clin Nephrol       Date:  1992-05       Impact factor: 0.975

7.  [The treatment of ankylosing spondylitis with auranofin (Ridaura)].

Authors:  K Grasedyck; M Schattenkirchner; K Bandilla
Journal:  Z Rheumatol       Date:  1990 Mar-Apr       Impact factor: 1.372

8.  Fine-needle aspiration biopsy from subcutaneous fat. An easy way to diagnose secondary amyloidosis.

Authors:  P J Klemi; S Sorsa; R P Happonen
Journal:  Scand J Rheumatol       Date:  1987       Impact factor: 3.641

9.  Secondary systemic amyloidosis: response and survival in 64 patients.

Authors:  M A Gertz; R A Kyle
Journal:  Medicine (Baltimore)       Date:  1991-07       Impact factor: 1.889

Review 10.  Amyloidosis in a case of ankylosing spondylitis with a review of the literature.

Authors:  N J Lance; J J Curran
Journal:  J Rheumatol       Date:  1991-01       Impact factor: 4.666

View more
  17 in total

Review 1.  Systemic amyloidosis: a challenge for the rheumatologist.

Authors:  Federico Perfetto; Alberto Moggi-Pignone; Riccardo Livi; Alessio Tempestini; Franco Bergesio; Marco Matucci-Cerinic
Journal:  Nat Rev Rheumatol       Date:  2010-06-08       Impact factor: 20.543

2.  Bone and stone in ankylosing spondylitis: osteoporosis and urolithiasis.

Authors:  Nurgül Arinci Incel; Figen Gökoğlu; Bariş Nacir; Nazmi Incel
Journal:  Clin Rheumatol       Date:  2005-12-07       Impact factor: 2.980

Review 3.  Pulmonary, renal and neurological comorbidities in patients with ankylosing spondylitis; implications for clinical practice.

Authors:  Cecilia Mercieca; Irene E van der Horst-Bruinsma; Andrew A Borg
Journal:  Curr Rheumatol Rep       Date:  2014-08       Impact factor: 4.592

Review 4.  [Prognosis and therapy of inflammatory rheumatic diseases : Impact of renal manifestations].

Authors:  M Zänker; C D Cohen; H D Rupprecht
Journal:  Z Rheumatol       Date:  2015-05       Impact factor: 1.372

5.  [Renal manifestations in rheumatic diseases].

Authors:  K de Groot
Journal:  Internist (Berl)       Date:  2007-08       Impact factor: 0.743

Review 6.  [Renal manifestations of rheumatic diseases].

Authors:  A Schwarting; E Märker-Hermann
Journal:  Z Rheumatol       Date:  2005-02       Impact factor: 1.372

7.  Secondary amyloidosis in ankylosing spondylitis.

Authors:  Salim Dönmez; Ömer Nuri Pamuk; Gülsüm Emel Pamuk; Erkan Aydoğdu; Robert Inman
Journal:  Rheumatol Int       Date:  2013-01-03       Impact factor: 2.631

8.  Factors associated with accelerated subclinical atherosclerosis in patients with spondyloarthritis without overt cardiovascular disease.

Authors:  Alessandro Giollo; Andrea Dalbeni; Giovanni Cioffi; Federica Ognibeni; Davide Gatti; Luca Idolazzi; Giovanni Orsolini; Pietro Minuz; Maurizio Rossini; Cristiano Fava; Ombretta Viapiana
Journal:  Clin Rheumatol       Date:  2017-09-09       Impact factor: 2.980

9.  Renal involvement in ankylosing spondylitis: prevalence, pathology, response to TNF-a blocker.

Authors:  Sang-Hoon Lee; Eun Jung Lee; Sang Wan Chung; Ran Song; Joo-Young Moon; Sang-Ho Lee; Sung-Jig Lim; Yeon-Ah Lee; Seung-Jae Hong; Hyung-In Yang
Journal:  Rheumatol Int       Date:  2012-12-27       Impact factor: 2.631

10.  The prevalence of comorbidity and predictors in ankylosing spondylitis.

Authors:  Gökşen Gökşenoğlu; Derya Buğdaycı; Nurdan Paker; Mustafa Aziz Yıldırım; Özlem Etli
Journal:  Turk J Phys Med Rehabil       Date:  2018-08-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.